FOLH1 and neoplasm: In addition to legal regulations, individual assessment of doses to OAR is mandatory for a patient-specific approach in PSMA-RLT and might allow for the administration of higher cumulative activities, thereby increasing doses to the tumor and hence improving response to therapy significantly as recently shown by several studies [8,9,10,11,12].